Pace Diagnostics

Revolutionary point-of-care, affordable early detection Lung cancer and Tuberculosis diagnostics

https://wefunder.com/pace.diagnostics

Total raised on Wefunder: 127079

Total investors: 111

Quick facts

  • Raised $2.5 million in seed investment; Won > $6 million in grants from US DoD, NIH, and NSF
  • Huge markets and financial opportunities: 3.1 billion USD tuberculosis & 20 billion USD lung cancer diagnostics in 2022
  • Our products - low cost, accurate, non-invasive, non-lab dependent lung cancer & tuberculosis tests
  • Our CE Mark is targeted for 2023, allowing product distribution in EU countries; clear path to FDA clinical trials
  • We have a portfolio of proprietary material, filed patents and licensed IPs
  • Each year: 10 million new TB infections & 2 million deaths; 2.1 million new Lung Cancer cases & 2 million new deaths
  • Our TB test is specifically developed to meet all WHO requirements for performance, cost and use
  • British Biocell International (BBI) is our manufacturing partner

Team profiles

Pace Diagnostics

Revolutionary point-of-care, affordable early detection Lung cancer and Tuberculosis diagnostics

Funded badge
Last Funded December 2022

$127,079

raised from 111 investors
Pitch Video
Investor Panel

Highlights

1
Raised $2.5 million in seed investment; Won > $6 million in grants from US DoD, NIH, and NSF
2
Huge markets and financial opportunities: 3.1 billion USD tuberculosis & 20 billion USD lung cancer diagnostics in 2022
3
Our products - low cost, accurate, non-invasive, non-lab dependent lung cancer & tuberculosis tests
4
Our CE Mark is targeted for 2023, allowing product distribution in EU countries; clear path to FDA clinical trials

Related company links

Team


Memo

Overview